

****REPRESENTATIVE DATASHEET******Sheep anti-human Factor VII (FVII)
Peroxidase Conjugated IgG
0.2 mg**

Product #: SAFVII-HRP
Lot #: XXXX
Expiry date: XXXX

Store at -10 to -20°C

1348 Sandhill Drive. Ancaster, Ontario, Canada L9G 4V5
905-304-9896 • 800-903-6020 • fax 905-304-9897

For Research Use Only.
Not for use in diagnostic procedures.

Description of Factor VII (FVII)

Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 µg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and F.XIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg¹⁵², resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and an 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate FX and FIX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of FXa, and also by Antithrombin (ATIII) in the presence of heparin¹⁻³.

REFERENCES and REVIEWS

1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.

Document OPI0075, rev 3

Product Specifications**Description:**

Vial containing XXXX ml of whole IgG conjugated to horseradish peroxidase (HRP) through carbohydrate groups. Total protein is 0.2 mg.

Format:

IgG-HRP conjugate as a clear, slightly red-brown liquid.

Host Animal:

Sheep

Immunogen:

Human FVII purified from plasma.

Concentration:

IgG-HRP concentration is XXXX mg/ml, determined by absorbance using an extinction coefficient ($E_{280}^{1\%}$) of 14.

Buffer:

A buffered stabilizer solution containing 50% (v/v) glycerol.

Storage:

Store between -10 and -20°C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use. Avoid exposure to sodium azide as this is an inhibitor of peroxidase activity.

Specificity:

Prior to conjugation, this antibody was specific for FVII as demonstrated by immunoelectrophoresis and ELISA.

Applications:

Suitable as a source of peroxidase-labeled antibodies to human FVII.

Rz Ratio (Reinheitszahl, A₄₀₃/A₂₈₀):

XXXX as determined spectrophotometrically.

Related Products:

| | |
|------------------|---|
| Cat #: SAFVII-IG | Sheep anti-human FVII, whole IgG from antiserum |
| Cat #: SAFVII-AP | Sheep anti-human FVII, affinity-purified IgG |
| Cat #: FVII-EIA | Paired antibody set for ELISA of FVII, 5 x 96 wells |
| Cat #: FVII-DP | Human plasma deficient in FVII, immune depleted |
| Cat #: FVII-AG | VisuLize FVII Antigen ELISA Kit |

Visit our site (www.affinitybiologicals.com) for details.

Limited Warranty: This product is warranted to perform in accordance with its labeling and literature. Affinity Biologicals Inc. disclaims any implied warranty of merchantability or fitness for any other purposes, and in no event will Affinity Biologicals Inc. be liable for any consequential damages arising out of aforesaid express warranty.

Manufactured in Canada by:
AFFINITY BIOLOGICALS INC.
1348 Sandhill Drive
Ancaster ON
CANADA L9G 4V5
Tel: (905) 304-9896
(800) 903-6020
Fax: (905) 304-9897
info@affinitybiologicals.com